Syneos Health eyes sale of company as contract backlog shrinks – Reuters News Agency

[ad_1]

DealsHealth

Shares of Syneos Health Inc rose 13% after Reuters exclusively reported that the company is making a new effort to sell itself. The effort comes in the wake of a reduced backlog of contracts for providing clinical research to drug developers that led to a plunge in the value of its shares over the past year. Syneos has hired Bank of America Corp and Centerview Partners LLC for financial advice as it embarks on a new round of talks with potential acquirers that may include industry peers and private equity firms. 

Market Impact

Syneos shares rose 13% on the news in morning trade to $43.35 a share at the time of reporting.

Article Tags

Topics of Interest: DealsHealth

Type: Reuters Best

Sectors: Business & FinancePharmaceuticals & Healthcare

Regions: Americas

Countries: United States

Win Types: Exclusivity

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Significant National Story

[ad_2]

Source link

Leave a Comment